Results 251 to 260 of about 234,176 (365)

2-Chlorodeoxyadenosine as treatment of severe acute graft-versus-host disease [letter] [PDF]

, 1994
Misha Pless, Aloïs Gratwohl, André Tichelli, B Speck, DC Betticher   +4 more
openalex   +1 more source

Gut microbiota‐derived butyrate mediates the anticolitic effect of indigo supplementation through regulating CD4+ T cell differentiation

iMeta, EarlyView.
This study explored the effect of plant‐derived indigo supplementation on intestinal inflammation using in vivo, in vitro, and clinical sample analyses. Our results showed that indigo decreased mucosal inflammation by regulating CD4+ T cell differentiation in a gut microbiota‐dependent manner.
Yunqi Xing, Muyuan Wang, Yali Yuan, Jiayan Hu, Zhibin Wang, Zhongmei Sun, Mengyu Zheng, Lei Shi, Junxiang Li, Tangyou Mao   +9 more
wiley   +1 more source

¹⁸F-FLT PET in Gastrointestinal Graft versus Host Disease: An Emerging Paradigm. [PDF]

Radiol Imaging Cancer
Pantel AR, Tischfield DJ.
europepmc   +1 more source

An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. [PDF]

, 1994
Scott R. Burrows, Rajiv Khanna, Jacqueline M. Burrows, Denis J. Moss   +3 more
openalex   +1 more source

Gut microbiota‐derived butyric acid regulates calcific aortic valve disease pathogenesis by modulating GAPDH lactylation and butyrylation

iMeta, EarlyView.
Multi‐omics sequencing and correlation analysis identified the beneficial role of Faecalibacterium prausnitzii (F. prausnitzii)‐derived butyric acid (BA) as a key metabolite in the restoration of valve function in calcific aortic valve disease (CAVD). The therapeutic efficacy of BA in attenuating CAVD progression was confirmed in vitro, ex vivo, and in
Chunli Wang, Zongtao Liu, Tingwen Zhou, Jiaqin Wu, Fan Feng, Shunshun Wang, Qingjia Chi, Yongqiang Sha, Shuai Zha, Songren Shu, Linghang Qu, Qianqian Du, Huiming Yu, Li Yang, Anna Malashicheva, Nianguo Dong, Fei Xie, Guixue Wang, Kang Xu   +18 more
wiley   +1 more source

THE EFFECT OF T SUBSET DEPLETION ON THE INCIDENCE OF LETHAL GRAFT-VERSUS-HOST DISEASE IN AMURINE MAJOR-HISTOCOMPATIBILITY-COMPLEX-MISMATCHED TRANSPLANTATION SYSTEM

, 1987
Daniel Pietryga, Bruce R. Blazar, CHRISTINE C. B. SODERLING, Daniel A. Vallera   +3 more
openalex   +1 more source

Research progress of antibody coupling technique in targeted drug delivery

Interdisciplinary Medicine, EarlyView.
Abstract Antibody‐drug conjugates are a cutting‐edge biotechnology recently attracting wide attention in the medical field. Binding antibodies to drug molecules could deliver drugs precisely to the site of the lesion, which shows great potential in the treatment of tumors and immune diseases.
Meng Li, Tiantian Wang, Dan Tan, Mengqi Wang, Changhai Lei, Yuqing Wang, Shi Hu   +6 more
wiley   +1 more source

Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. [PDF]

Clin Exp Med
Raoufi A, Soleimani Samarkhazan H, Nouri S, Khaksari MN, Abbasi Sourki P, Sargazi Aval O, Baradaran B, Aghaei M.   +7 more
europepmc   +1 more source

Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation [PDF]

, 1990
K Atkinson, MM Horowitz, Gale Rp, DW van Bekkum, Éliane Gluckman, Good Ra, N Jacobsen, HJ Kolb, AA Rimm, Olle Ringdén   +9 more
openalex   +1 more source

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

The Journal of Clinical Pharmacology, EarlyView.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller, Lauren Lohmer, Felix Beck, Jeegar Patel, Jasminder Sahi   +4 more
wiley   +1 more source